Last week, Fluicell took part in the inaugural Breakthrough T1D Clinical & Research Congress in Philadelphia, which brought together leading researchers and clinicians from across the type 1 diabetes field.
We spent the days in exciting conversations with partners, collaborators and industry leaders about where T1D therapeutics are heading. Cell therapy is clearly gaining momentum in type 1 diabetes treatment, and our islet engineering technology occupies a unique niche.
Thank you to Breakthrough T1D for organizing the congress and for the opportunity to present our research. We’re already looking forward to the next one.